ELVN · Enliven Therapeutics, Inc.
← all insidersPharmaceutical Preparations · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades29
Distinct insiders5
Bought$0
Sold$63.46M
Net flow$-63.46M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 1,3880 | $59.35 | $82.4K | 40,036 | −3% | −<0.01% (now 0.05%) | filing |
| 2026-08-19 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 4,6300 | $58.35 | $270.2K | 41,424 | −10% | −<0.01% (now 0.06%) | filing |
| 2026-08-19 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 5,000→ 5,000 Common Stock | — | — | 111,268 | — | — | filing |
| 2026-08-19 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 1,1000 | $59.35 | $65.3K | 25,000 | −4% | −<0.01% (now 0.03%) | filing |
| 2026-08-19 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 3,9000 | $58.37 | $227.6K | 26,100 | −13% | −<0.01% (now 0.04%) | filing |
| 2026-08-19 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 5,0000 | $2.48 | $12.4K | 30,000 | +20% | +<0.01% (now 0.04%) | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▼ sell10b5-1 | 20,491→ 20,491 Common Stock | — | — | 0 | — | — | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▼ sell10b5-1 | 23,364→ 23,364 Common Stock | — | — | 0 | — | — | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▼ sell10b5-1 | 27,567→ 27,567 Common Stock | — | — | 0 | — | — | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▼ sell10b5-1 | 87,373→ 87,373 Common Stock | — | — | 0 | — | — | filing |
| 2026-08-06 | Derynck Mika K | Director | S | ▼ sell10b5-1 | 158,7950 | $60.21 | $9.56M | 0 | −100% | −0.22% (now 0%) | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▲ buy10b5-1 | 20,4910 | $22.47 | $460.4K | 158,795 | +15% | +0.03% (now 0.22%) | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▲ buy10b5-1 | 23,3640 | $14.85 | $347.0K | 138,304 | +20% | +0.03% (now 0.19%) | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▲ buy10b5-1 | 27,5670 | $25.28 | $696.9K | 114,940 | +32% | +0.04% (now 0.16%) | filing |
| 2026-08-06 | Derynck Mika K | Director | M | ▲ buy10b5-1 | 87,3730 | $2.48 | $216.7K | 87,373 | new | +0.12% (now 0.12%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | M | ▼ sell10b5-1 | 1,072→ 1,072 Common Stock | — | — | 84,966 | — | — | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 1230 | $53.87 | $6.6K | 46,054 | −0.3% | −<0.01% (now 0.06%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 2,6380 | $53.38 | $140.8K | 46,177 | −5% | −<0.01% (now 0.06%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 2,5640 | $52.32 | $134.1K | 48,815 | −5% | −<0.01% (now 0.07%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 3690 | $51.48 | $19.0K | 51,379 | −0.7% | −<0.01% (now 0.07%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 3240 | $49.97 | $16.2K | 51,748 | −0.6% | −<0.01% (now 0.07%) | filing |
| 2026-07-21 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | M | ▲ buy10b5-1 | 1,0720 | $2.48 | $2.7K | 52,072 | +2% | +<0.01% (now 0.07%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 5,000→ 5,000 Common Stock | — | — | 116,268 | — | — | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 630 | $53.92 | $3.4K | 25,000 | −0.3% | −<0.01% (now 0.03%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2,1840 | $53.42 | $116.7K | 25,063 | −8% | −<0.01% (now 0.03%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2,0630 | $52.39 | $108.1K | 27,247 | −7% | −<0.01% (now 0.04%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 4590 | $51.55 | $23.7K | 29,310 | −2% | −<0.01% (now 0.04%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2310 | $50.05 | $11.6K | 29,769 | −0.8% | −<0.01% (now 0.04%) | filing |
| 2026-07-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 5,0000 | $2.48 | $12.4K | 30,000 | +20% | +<0.01% (now 0.04%) | filing |
| 2026-07-08 | Kunkel Lori Anne | Director | S | ▼ sell10b5-1 | 5,8890 | $50.84 | $299.4K | 41,884 | −12% | −<0.01% (now 0.06%) | filing |
| 2026-07-08 | Kunkel Lori Anne | Director | S | ▼ sell10b5-1 | 4,1110 | $49.98 | $205.5K | 47,773 | −8% | −<0.01% (now 0.07%) | filing |
| 2026-06-24 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 46,7760 | $45.00 | $2.10M | 6,555,102 | −0.7% | −0.06% (now 8.9%) | filing |
| 2026-06-24 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 787,0240 | $45.38 | $35.72M | 6,601,878 | −11% | −1.1% (now 9.0%) | filing |
| 2026-06-24 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 1,4770 | $45.00 | $66.5K | 219,405 | −0.7% | −<0.01% (now 0.30%) | filing |
| 2026-06-24 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 24,8460 | $45.38 | $1.13M | 220,882 | −10% | −0.03% (now 0.30%) | filing |
| 2026-06-22 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | M | ▼ sell10b5-1 | 6,018→ 6,018 Common Stock | — | — | 86,038 | — | — | filing |
| 2026-06-22 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 1,2380 | $44.75 | $55.4K | 51,000 | −2% | −<0.01% (now 0.07%) | filing |
| 2026-06-22 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 3,4010 | $43.86 | $149.2K | 52,238 | −6% | −<0.01% (now 0.07%) | filing |
| 2026-06-22 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | S | ▼ sell10b5-1 | 1,3790 | $42.79 | $59.0K | 55,639 | −2% | −<0.01% (now 0.08%) | filing |
| 2026-06-22 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | M | ▲ buy10b5-1 | 6,0180 | $2.48 | $14.9K | 57,018 | +12% | +<0.01% (now 0.08%) | filing |
| 2026-06-22 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 5,000→ 5,000 Common Stock | — | — | 121,268 | — | — | filing |
| 2026-06-22 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 1,1330 | $44.74 | $50.7K | 25,000 | −4% | −<0.01% (now 0.03%) | filing |
| 2026-06-22 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2,5990 | $43.87 | $114.0K | 26,133 | −9% | −<0.01% (now 0.04%) | filing |
| 2026-06-22 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 1,2680 | $42.83 | $54.3K | 28,732 | −4% | −<0.01% (now 0.04%) | filing |
| 2026-06-22 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 5,0000 | $2.48 | $12.4K | 30,000 | +20% | +<0.01% (now 0.04%) | filing |
| 2026-06-17 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 272,3220 | $45.02 | $12.26M | 7,388,902 | −4% | −0.37% (now 10%) | filing |
| 2026-06-17 | ORBIMED ADVISORS LLC +2 more | 10% owner | S | ▼ sell | 9,0860 | $45.02 | $409.1K | 245,728 | −4% | −0.01% (now 0.34%) | filing |
| 2026-06-09 | Kunkel Lori Anne | Director | S | ▼ sell10b5-1 | 3540 | $35.82 | $12.7K | 51,884 | −0.7% | −<0.01% (now 0.07%) | filing |
| 2026-06-09 | Kunkel Lori Anne | Director | S | ▼ sell10b5-1 | 1,8670 | $35.36 | $66.0K | 52,238 | −3% | −<0.01% (now 0.07%) | filing |
| 2026-06-09 | Kunkel Lori Anne | Director | S | ▼ sell10b5-1 | 7,7790 | $34.28 | $266.7K | 54,105 | −13% | −0.01% (now 0.07%) | filing |
| 2026-05-20 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 5,000→ 5,000 Common Stock | — | — | 126,268 | — | — | filing |
| 2026-05-20 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2230 | $41.21 | $9.2K | 25,000 | −0.9% | −<0.01% (now 0.03%) | filing |
| 2026-05-20 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 1,3020 | $40.25 | $52.4K | 25,223 | −5% | −<0.01% (now 0.03%) | filing |
| 2026-05-20 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 3,4750 | $39.53 | $137.4K | 26,525 | −12% | −<0.01% (now 0.04%) | filing |
| 2026-05-20 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 5,0000 | $2.48 | $12.4K | 30,000 | +20% | +<0.01% (now 0.04%) | filing |
| 2026-04-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 5,000→ 5,000 Common Stock | — | — | 131,268 | — | — | filing |
| 2026-04-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2,4410 | $48.06 | $117.3K | 25,000 | −9% | −<0.01% (now 0.03%) | filing |
| 2026-04-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 2,4190 | $47.39 | $114.6K | 27,441 | −8% | −<0.01% (now 0.04%) | filing |
| 2026-04-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 1400 | $45.81 | $6.4K | 29,860 | −0.5% | −<0.01% (now 0.04%) | filing |
| 2026-04-21 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 5,0000 | $2.48 | $12.4K | 30,000 | +20% | +<0.01% (now 0.04%) | filing |
| 2026-03-27 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▼ sell10b5-1 | 40,000→ 40,000 Common Stock | — | — | 136,268 | — | — | filing |
| 2026-03-27 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | S | ▼ sell10b5-1 | 40,0000 | $35.10 | $1.40M | 25,000 | −62% | −0.05% (now 0.03%) | filing |
| 2026-03-27 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | M | ▲ buy10b5-1 | 40,0000 | $2.48 | $99.2K | 65,000 | 2.6× | +0.05% (now 0.09%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.